IMV

IMV

Contact:  rkhalek@imv-inc.com
Website:  imv-inc.com

Overview

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the reprogramming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently conducting three Phase 2 studies with Incyte and Merck assessing DPX-Survivac as a combination therapy in ovarian cancer and diffuse large B-cell lymphoma. For more information, please connect at: www.imv-inc.com

Industry: Biotechnology

Headquarters: Dartmouth, Nova Scotia

Type: Public Company

Founded: 2000

Specialties: Immunotherapy, DPX Platform, Infectious Diseases, and Animal Health

Skills

Posted on

December 1, 2004